Real-World Efficacy of Ustekinumab vs Vedolizumab for Ulcerative Colitis

figshare admin karger provides supplementary material for a study comparing two biologic therapies for ulcerative colitis. The dataset includes outcomes for 197 patients from two tertiary centers over a median observation period of 2.5 years. It was last updated in May 2026.

Use Cases

• Compare endoscopic remission rates based on Mayo Endoscopic Subscore (MES) criteria between two drug cohorts.
• Analyze treatment persistence patterns based on hazard ratios and confidence intervals provided in the study.
• Model long-term clinical outcomes based on patient data from two tertiary medical centers.

Strengths

• Includes data from 197 patients, with 96 receiving ustekinumab and 101 receiving vedolizumab.
• Reports outcomes at 1-year and 2-year intervals, with a median observation period of 2.5 years.
• Uses inverse probability of treatment weighting to adjust for baseline imbalances.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• Data may reflect temporal or institutional bias inherent to the two-source, retrospective study design.

Provenance

Source

figshare admin karger

Collection Method

Retrospective study of patients treated at two tertiary centers.

Time Range

The median observation period was 2.5 years.

Freshness

Last updated 2026-05-04 07:55:15; freshness should be verified.